PT - JOURNAL ARTICLE AU - Lee, Sung Uk AU - Seong, Jinsil AU - Kim, Tae Hyun AU - Im, Jung Ho AU - Kim, Woo Chul AU - Kim, Kyubo AU - Park, Hae Jin AU - Kim, Tae Gyu AU - Kim, Youngkyong AU - Jeong, Bae Kwon AU - Kim, Jin Hee AU - Kim, Byoung Hyuck AU - Nam, Taek-Keun TI - Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04) AID - 10.20892/j.issn.2095-3941.2020.0667 DP - 2022 Jun 15 TA - Cancer Biology & Medicine PG - 931--944 VI - 19 IP - 6 4099 - http://www.cancerbiomed.org/content/19/6/931.short 4100 - http://www.cancerbiomed.org/content/19/6/931.full SO - Cancer Biology & Medicine2022 Jun 15; 19 AB - Objective: The effectiveness of adjuvant treatments for resected gallbladder carcinoma (GBC) has remained unclear due to lack of randomized controlled trials; thus, the aim of present study was to evaluate the role of adjuvant treatments, including chemoradiotherapy (CRT) and/or chemotherapy (CTx), in patients with resected GBC.Methods: A total of 733 GBC patients who received curative-intent surgical resection were identified in a multi-institutional database. Of 733 patients, 372 (50.8%) did not receive adjuvant treatment, whereas 215 (29.3%) and 146 (19.9%) received adjuvant CTx and CRT, respectively. The locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), and overall survival (OS) of the adjuvant treatment groups were compared according to tumor stage (stage II vs. stage III–IV).Results: In stage II disease (n = 381), the 5-year LRFS, RFS, and OS were not significantly different among the no-adjuvant therapy, CTx, and CRT groups, and positive resection margin, presence of perineural invasion, and Nx classification were consistently associated with worse LRFS, RFS, and OS in the multivariate analysis (P < 0.05). For stage III–IV (n = 352), the CRT group had significantly higher 5-year LRFS, RFS, and OS than the no-adjuvant therapy and CTx groups (67.8%, 45.2%, and 56.9%; 37.9%, 28.8%, and 35.4%; and 45.0%, 30.0%, and 45.7%, respectively) (P < 0.05).Conclusions: CRT has value as adjuvant treatment for resected GBC with stage III–IV disease. Further study is needed for stage II disease with high-risk features.